18 results about "Albendazole" patented technology

The invention discloses an albendazole-ivermectin compound nanoemulsion and a preparation method of the albendazole-ivermectin compound nanoemulsion. The albendazole-ivermectin nanoemulsion is prepared from albendazole, ivermectin, an oil phase, a surfactant, a cosurfactant and a water phase. The preparation method comprises the following steps: dissolving the medicines in a solvent, extracting to obtain an oil phase, removing the solvent, adding the oil phase into a water phase consisting of the surfactant, the cosurfactant and water under stirring, and spontaneously forming the nano-emulsion through low-energy emulsification. The prepared nanoemulsion is small in particle size and good in stability, the solubility and the drug loading capacity of two insoluble drugs can be remarkably improved, the synergistic parasite expelling effect is achieved, and the cure rate is increased. The preparation process is simple, mild in condition and suitable for industrial production.

The present application belongs to the technical field of veterinary medicine, and relates to a kind of veterinary albendazole tablets, and the preparation method of the preparation is provided.The tablet is composed of albendazole, trehalose, sodium taurocholate and other pharmaceutically acceptable binders, disintegrants and lubricants.By spray drying the mixed solution of albendazole, trehalose and sodium taurocholate, the albendazole is fully dispersed, and the amount of trehalose and sodium taurocholate is controlled, which improves the dissolution and stability of the product.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an albendazole dispersing agent and a preparation method thereof. The preparation method comprises the following steps: uniformly mixing and dispersing a modified phospholipid compound, a membrane regulator, albendazole and absolute ethyl alcohol, and performing rotary evaporation to obtain the lipid membrane, and adding normal saline into the lipid membrane, mixing and hydrating to obtain the albendazole dispersing agent. Through the technical means of the invention, the albendazole dispersing agent not only has good encapsulation efficiency and storage stability, but also has good in-vitro release performance, and the drug effect can be quickly exerted.

The invention discloses a quantitative analysis method for the content of crystal forms in an albendazole preparation. Specifically, the invention provides a quantitative analysis method for the crystal form content in an albendazole preparation, which comprises the following steps: (1) collecting a near infrared spectrogram of an ABZ preparation sample; (2) establishing a quantitative analysis model; and (3) quantitative analysis of the ABZ crystal form in the ABZ preparation. According to the quantitative analysis method for the crystal form content in the albendazole preparation, the crystal form content in the albendazole preparation is rapidly and quantitatively analyzed on the basis of a PLS multivariate linear correction method and a near infrared spectrum, the crystal form content in the albendazole preparation can be rapidly and efficiently detected without being limited by regions and being detected by high-tech operators, and the medicine quality is controlled.

This invention discloses a method for preparing albendazole, belonging to the field of pharmaceutical preparation technology. The method includes: (1) cyclization reaction: using methyl cyanocarbamate and 4-(propylthio)phenyl-1,2-diamine or their hydrochloride as raw materials, reacting in water, methanol, ethanol or a mixed solvent in the presence of an acidic catalyst or an alkaline buffer; (2) crystallization and separation of crude product: adjusting the pH of the reaction solution to 3-5, and separating the solid and liquid to obtain the crude product; (3) washing and purification: the crude product is washed successively with toluene, methanol and water, and dried to obtain the purified product; (4) refining and post-treatment: dissolving, decolorizing and recrystallizing with a formic acid-water mixed solvent, drying, pulverizing and sieving, and packaging to obtain the finished product. This invention uses a green and environmentally friendly solvent system, suppresses side reactions through precise pH control, optimizes the three-stage washing and recrystallization process, achieves a molar yield of over 88%, a purity of 99.85%, meets pharmaceutical standards, and is suitable for large-scale production.

This invention relates to the field of veterinary drugs, specifically to an albendazole-ivermectin premix and its preparation method. The premix, by weight percentage (100%), comprises the following raw materials: albendazole 9.5-10.5%, ivermectin microcapsules 0.19-0.21%, sodium chloride 12-24%, and the balance being modified starch. The albendazole-ivermectin premix prepared by this invention can be uniformly mixed through a simple process, exhibiting high homogeneity.

The utility model discloses a mixer for mixing albendazole ivermectin premix, which comprises a machine body, a hopper and a valve device, the hopper is arranged at the lower end of the machine body, fixedly connected with the machine body and communicated with the machine body, and the valve device is arranged at the upper end of the hopper and fixedly connected with the hopper. The machine body, the hopper, the valve device, the auxiliary device, the slapping assembly, the rotating seat, the slapping plate, the tension spring, the linkage assembly, the supporting seat, the rotating rod, the extrusion wheel, the control assembly, the supporting plate, the motor, the first belt wheel, the second belt wheel and the rubber block are used in cooperation. The problems that in the prior art, a part of premixing agent is left and attached to the inner wall of the hopper and cannot be well treated, so that discharging of the hopper is not thorough, and the part of premixing agent is wasted are solved.

The invention provides a parasite expelling composition and application thereof in yak breeding, the parasite expelling composition comprises albendazole and myrobalan acid, through the synergistic effect of albendazole and myrobalan acid, on one hand, the myrobalan acid inhibits the activity of liver microsome metabolic enzymes, prolongs the half-life period of albendazole, improves the bioavailability and optimizes the pharmacokinetic process, on the other hand, the myrobalan acid inhibits the activity of liver microsome metabolic enzymes, and on the other hand, the myrobalan acid inhibits the activity of liver microsome metabolic enzymes; on the other hand, the two act on parasite tubulin synthesis and a body surface biofilm structure respectively to form double-target synergistic killing, so that the parasite expelling effect is remarkably improved; chebulinic acid can repair gastrointestinal mucosa, regulate flora balance, enhance appetite and effectively counteract irritant injury of albendazole to gastrointestinal tracts; the parasite expelling rate reaches 95% or above, the average daily gain reaches 369 g / d, and no obvious influence is caused to the blood system and liver and kidney functions of yaks; the composition has the characteristics of simple formula, gastrointestinal protection and convenience in administration, is adaptive to the current breeding situation of high parasite infection rate of yaks in plateau pasturing areas, and has a good industrial application prospect.

The invention relates to the technical field of biological manufacturing of veterinary bulk drugs, and discloses an immobilized enzyme catalyst-based albendazole side chain oriented synthesis process, which comprises a magnetic core; the proton channel array functional layer is coated on the substrate and is made of a metal organic framework material; the flexible molecular arm is connected to the outer surface of the functional layer; and a primary catalytic enzyme and a coenzyme regenerating enzyme covalently bonded by a flexible molecular arm. In a reaction medium, the catalyst, a substrate 5-(propylthio)-1H-benzo [d] imidazole-2-amine, glucose and a coenzyme NADP < + > are subjected to a catalytic reaction under mild conditions. The pH value of a double-enzyme catalysis microenvironment is stabilized through a proton channel constructed by a ZIF-8 layer, the activity loss in the enzyme immobilization process is reduced through the design of a flexible molecular arm, and the catalyst is conveniently recycled through a magnetic core. The process has the advantages of mild reaction conditions, high product selectivity, good catalyst operation stability and repeated use.

The application discloses albendazole and ivermectin premix and a preparation method thereof. The premix comprises albendazole 8-15%, ivermectin 0.2-0.4%, double-layer inclusion carrier 20-30% and various auxiliary materials in percentage by mass. The application adopts the double-layer inclusion carrier formed by inner layer hydroxypropyl-beta-cyclodextrin and outer layer hydroxypropyl methylcellulose phthalate and povidone K30 to form an enteric barrier. The preparation method comprises the steps of inner layer inclusion, outer layer dispersion, mixing and granulation. The relative bioavailability of the premix reaches 203%-221%, the pig ascarid drive rate is 98.7%-99.5%, the scabies mite negative conversion rate is 98%-100%, the diarrhea incidence is only 2%-3%, the premix is safe for pregnant sow groups, and no adverse reactions such as abortion, premature birth and loss of appetite occur in all test pigs during the test period. The problems of uneven mixing, low bioavailability and large side effects of traditional preparations are solved, and the premix is suitable for livestock and poultry parasite prevention and treatment.

This invention relates to the field of veterinary drug technology, and proposes a compound composition for the prevention and treatment of shrimp hepatocellular carcinoma and its preparation method. The compound composition comprises the following raw materials: albendazole, ivermectin, and glycyrrhizic acid monoammonium salt. The components in the compound composition for the prevention and treatment of shrimp hepatocellular carcinoma provided by this invention work synergistically to safely control the disease and ensure the healthy and sustainable development of aquaculture.

The invention relates to the field of medicine crystal forms, in particular to an albendazole-acesulfame potassium salt crystal form A, a preparation method and application. The molar ratio of the albendazole anion to the acesulfame cation in the salt structure is 1: 1. The crystal form A of the albendazole-acesulfame potassium salt prepared by the preparation method disclosed by the invention has relatively good dissolving property and relatively good flowability. Meanwhile, the preparation method is simple, good in reproducibility, low in cost and environment-friendly.

The invention discloses a method for detecting the crystal form content of albendazole. According to the method, an infrared paste method is adopted, an albendazole sample to be detected, an albendazole crystal form I reference substance and an albendazole crystal form II reference substance are uniformly mixed into paste in an agate mortar by using liquid paraffin, the sample paste is filled into a liquid pool, the liquid paraffin is used for preparing a blank, an infrared spectrometer is used for collecting an instrument background, and the liquid paraffin is used for detecting the albendazole crystal form I reference substance and the albendazole crystal form II reference substance. And then carrying out absorbance collection on the sample and the reference substance. The method has the advantages of simplicity and convenience in operation, high analysis speed, high sensitivity, good repeatability, accurate and reliable data and the like.

The invention discloses a surface-modified screen-printed electrode, a preparation method and application of the surface-modified screen-printed electrode in albendazole detection, and belongs to the technical field of electrochemical sensing. The method comprises the following steps: firstly, dropwise adding a hydrogen peroxide solution to the surface of a working electrode of a screen-printed electrode for modification treatment to obtain a modified working electrode; washing the surface of the modified working electrode with ultrapure water and drying; and finally, dispensing the multi-walled carbon nanotube dispersion liquid on the surface of the modified working electrode, and drying to obtain the surface-modified screen-printed electrode. Mild pretreatment is carried out through the hydrogen peroxide solution with the specific mass fraction (5-30%), the surface contact angle of the screen-printed electrode can be remarkably reduced, and the screen-printed electrode becomes hydrophilic from hydrophobic; an ideal interface is created for uniform loading of a multiwalled carbon nanotube aqueous nano material dispersion liquid, and the core problem that a modification layer is easy to agglomerate and fall off is solved; the pretreatment thought provides a universal interface solution for construction of various electrochemical sensing platforms based on screen-printed electrodes.

This invention relates to the field of pharmaceutical premixes, addressing the problem in existing technologies of simultaneously ensuring uniform dispersion of the active pharmaceutical ingredient during preparation and when the premix is ​​used with drinking water. It provides an albendazole-ivermectin premix and its preparation method, comprising the following steps: S100, dissolving ivermectin in ethanol to obtain a first solution; adding albendazole and water to the first solution to obtain a first suspension; S200, adding an adjuvant to the first suspension to obtain a second suspension; S300, mixing the second suspension with a soluble carrier, and then granulating to obtain the albendazole-ivermectin premix. This invention, by dissolving ivermectin in a mixed solvent of ethanol and water, ensures the uniformity of ivermectin in the solution system. Furthermore, when mixing the solution with a soluble carrier, it significantly improves the uniformity of ivermectin within the carrier, allowing for more precise dosage of ivermectin when using the albendazole-ivermectin premix.

The invention relates to the technical field of pharmaceutical compositions, in particular to an albendazole suspension preparation and a preparation method thereof.The albendazole suspension preparation is obtained by mixing an albendazole inclusion compound, propylene glycol, a thickener, an emulsifier, a preservative, a stabilizer, a suspending aid, an antioxidant, deionized water and an acidity regulator, the albendazole clathrate compound is prepared from albendazole, chitosan and hydroxypropyl-beta-cyclodextrin, the hydroxypropyl-beta-cyclodextrin has a hydrophilic outer surface and a lipophilic central cavity, and the hydrophobic interaction of the hydroxypropyl-beta-cyclodextrin can accommodate a lipophilic drug albendazole, so that the solubility and the stability of the albendazole can be effectively improved, and the albendazole clathrate compound can be used for preparing a medicine for treating the albendazole. The albendazole clathrate compound has the advantages that the albendazole clathrate compound is prepared from hydroxypropyl-beta-cyclodextrin and chitosan, the chitosan has mucous membrane adhesion, the stagnation time of the albendazole clathrate compound on gastrointestinal mucosa is prolonged by grafting the chitosan to the surface of the hydroxypropyl-beta-cyclodextrin, the absorbability and bioavailability of gastrointestinal tracts are further improved, the albendazole clathrate compound and the hydroxypropyl-beta-cyclodextrin have a synergistic effect, the drug effect of the albendazole is improved, and the albendazole clathrate compound has a wide application prospect.

The application discloses a kind of high bioavailability albendazole nanocrystals and preparation method thereof.The nanocrystals of the application are prepared by mixing albendazole, natural source glycoside stabilizer and water to form a suspension, and then using wet medium grinding.The average particle size is 100-500nm.The nanocrystals are obtained by dispersing albendazole in natural source glycoside solution and then nano-treating, with high drug loading, which can greatly improve the solubility and dissolution of albendazole, and then improve its absorption and bioavailability.The stabilizer used in the application is abundant in resources, natural and economical, and the preparation process is simple, efficient and safe, which is suitable for industrial production, and provides a high bioavailability intermediate for albendazole preparation.